Immutep Advances First-in-Human Phase I Study of IMP761 to Dose Escalation Phase
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company focused on LAG-3 immunotherapies, announced that its first-in-human Phase I study of IMP761 has progressed to the dose escalation phase. The study, conducted at the Centre for Human Drug Research (CHDR) in the Netherlands, involves administering increasing doses of IMP761 to healthy volunteers after the successful completion of the initial single-dose phase without safety concerns. IMP761, a novel immunosuppressive LAG-3 agonist antibody, aims to target the underlying cause of autoimmune diseases by silencing autoimmune memory T cells. First safety data is expected by the end of 2024, with additional pharmacokinetic and pharmacodynamic assessments anticipated in the first half of 2025.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders.
